Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy

2.

Den Boer

ML

,

van Slegtenhorst

M

,

De Menezes

RX

, et al.

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

.

Lancet Oncol

.

2009

;

10

(

2

):

125

-

134

.

3.

Mullighan

CG

,

Su

X

,

Zhang

J

, et al.

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

.

N Engl J Med

.

2009

;

360

(

5

):

470

-

480

.

4.

Hughes

TP

,

Mauro

MJ

,

Cortes

JE

, et al.

Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure

.

N Engl J Med

.

2019

;

381

(

24

):

2315

-

2326

.

5.

Hantschel

O

.

Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance

.

Haematologica

.

2012

;

97

(

2

):

157

-

159

.

6.

Hantschel

O

,

Nagar

B

,

Guettler

S

, et al.

A myristoyl/phosphotyrosine switch regulates c-Abl

.

Cell

.

2003

;

112

(

6

):

845

-

857

.

7.

Nagar

B

,

Hantschel

O

,

Young

MA

, et al.

Structural basis for the autoinhibition of c-Abl tyrosine kinase

.

Cell

.

2003

;

112

(

6

):

859

-

871

.

8.

Smith

KM

,

Yacobi

R

,

Van Etten

RA

.

Autoinhibition of Bcr-Abl through its SH3 domain

.

Mol Cell

.

2003

;

12

(

1

):

27

-

37

.

9.

Wylie

AA

,

Schoepfer

J

,

Jahnke

W

, et al.

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

.

Nature

.

2017

;

543

(

7647

):

733

-

737

.

10.

Eide

CA

,

Zabriskie

MS

,

Savage Stevens

SL

, et al.

Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants

.

Cancer Cell

.

2019

;

36

(

4

):

431

-

443.e435

.

11.

Zhang

J

,

Adrian

FJ

,

Jahnke

W

, et al.

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors

.

Nature

.

2010

;

463

(

7280

):

501

-

506

.

12.

Eadie

L

,

Saunders

V

,

Branford

S

,

White

D

,

Hughes

T

.

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro

.

Oncotarget

.

2018

;

9

(

17

):

13423

-

13437

.

13.

Heatley

SL

,

Asari

K

,

Schutz

CE

, et al.

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

.

Leuk Lymphoma

.

2021

;

62

(

5

):

1157

-

1166

.

14.

Roberts

KG

,

Li

Y

,

Payne-Turner

D

, et al.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

.

N Engl J Med

.

2014

;

371

(

11

):

1005

-

1015

.

15.

Roberts

KG

,

Yang

Y-L

,

Payne-Turner

D

, et al.

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

.

Blood Adv

.

2017

;

1

(

20

):

1657

-

1671

.

16.

Tanaka

C

,

Yin

OQ

,

Sethuraman

V

, et al.

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

.

Clin Pharmacol Ther

.

2010

;

87

(

2

):

197

-

203

.

17.

Cortes

JE

,

Kantarjian

H

,

Shah

N P

, et al.

Ponatinib in refractory Philadelphia chromosome–positive leukemias

.

N Engl J Med

.

2012

;

367

(

22

):

2075

-

2088

.

18.

Hoch

M

,

Huth

F

,

Sato

M

, et al.

Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents

.

Clin Transl Sci

.

2022

;

15

(

7

):

1698

-

1712

.